HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 282, Issue 36, 26046-26056, September 7, 2007

This Article Full Text Full Text (PDF) All Versions of this Article: 282/36/26046    most recent M703652200v2 M703652200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xu, Y. Articles by Smith, B. D. Search for Related Content PubMed PubMed Citation Articles by Xu, Y. Articles by Smith, B. D. Social Bookmarking                      What's this?

Peroxisome Proliferator-activated Receptor Interacts with CIITA·RFX5 Complex to Repress Type I Collagen Gene Expression^*

From the Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts 02118

Recent reports demonstrate that peroxisome proliferator-activated receptor (PPAR), a member of the nuclear receptor superfamily, acts as a repressor of type I collagen synthesis. Our data demonstrate that exogenously expressed PPAR down-regulates collagen expression in a dose-responsive manner in human lung fibroblast cells. Silencing PPAR using lentiviruses expressing short hairpin RNAs partially reverses interferon- (IFN-)-induced repression and activates collagen mRNA levels. Previous studies indicate that IFN- represses collagen gene expression and induces major histocompatibility complex II (MHC II) expression by activating the formation of a regulatory factor for X-box 5 (RFX5) complex with class II transactivator (CIITA). This report demonstrates that PPAR is within the RFX5·CIITA complex as judged by co-immunoprecipitation and DNA affinity precipitation studies. Most importantly, occupancy of PPAR on the collagen transcription start site and MHC II promoter increases with IFN- treatment. The PPAR agonist, troglitazone, sensitizes the cells to IFN- treatment by increasing recruitment of PPAR to collagen gene while repressing collagen expression, and these effects are blocked by the PPAR antagonist T0070907. PPAR may mediate IFN--stimulated collagen transcription down-regulation and MHC II up-regulation by interacting with CIITA as well as regulating CIITA expression. Therefore, PPAR is a critical target for investigations into therapeutics of diseases involving extracellular matrix remodeling and the immune response.

Received for publication, May 2, 2007 , and in revised form, June 28, 2007.

^* This work was supported by National Institutes of Health (NIH) Public Health Services Grants HL68094 and HL013262–31 (to B. D. S.), by NHLBI, NIH Grants DK51586 and DK58825 (to S. R. F.), by the NIDDK, NIH, and by American Heart Association post-doctoral fellowship Grant 0525981T (to Y. X.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom correspondence should be addressed: Dept. of Biochemistry, Boston University School of Medicine, 715 Albany St., Boston, MA 02118. Tel.: 617-638-4159; Fax: 617-638-5339; E-mail: smith{at}biochem.bumc.bu.edu.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				Y. Xu, K. Ravid, and B. D. Smith Major Histocompatibility Class II Transactivator Expression in Smooth Muscle Cells from A2b Adenosine Receptor Knock-out Mice: CROSS-TALK BETWEEN THE ADENOSINE AND INTERFERON-{gamma} SIGNALING J. Biol. Chem., May 23, 2008; 283(21): 14213 - 14220. [Abstract] [Full Text] [PDF]